Gilead Sciences, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report3 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Gilead Sciences, Inc.
170.40
−0.28 · −0.17%
post 171.00 +0.35%
Expected move
Inputsspot 170.33exp Feb 19ATM strike 170ATM straddle 23.93IV 33%
+3.06%
vs ±3.4% implied · ×0.89
shaded = implied · ▲▼ = realized
Gilead Sciences has 16 disclosed suppliers and 10 disclosed customers in SEC filings.
SentenceThe revenues from our collaboration partner Gilead represented 97 % of our total net revenues from continuing operations in 2025 ( 87 % in 2024, nearly 100 % in 2023). The remaining 3 % of the net revenues in 2025 ( 13 % in 2024) consisted of supply revenues of Jyseleca® products to Alfasigma (Italy).
basisLKFT FY2025 revenue $1.3BGILD FY2025 revenue $29.4B
SentenceAs part of the Gilead Agreement, Gilead paid us a non-refundable upfront payment of $60.0 million and we are eligible to receive up to $1.7 billion in target nomination, option fees, and development, regulatory and commercial milestones, assuming Gilead exercises the CD123 Option and Research Program Option, successfully develops and commercializes MGD024 or other CD123 products developed under the agreement, and products result from the two additional research programs .
SentenceIn 2020, we and Gilead entered into the Gilead Collaboration Agreement, as amended, under which Gilead obtained an exclusive license to zimberelimab and time-limited exclusive options to all of our then-current and future programs during the collaboration term.
SentenceOur life sciences customers range from the largest global pharmaceutical and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes Inc., Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and Idorsia Pharmaceuticals Ltd.
SentenceAcquired in-process research and development expenses were $4.7 billion in 2024, primarily related to the following transactions: • $3.8 billion CymaBay acquisition; • $320 million Janssen Pharmaceutica NV future royalty obligation extinguishment related to seladelpar; • $100 million Arcus Biosciences, Inc. collaboration continuation fee; • $68 million Arcellx, Inc. ("Arcellx") collaboration milestones met; and • $47 million Tmunity Therapeutics, Inc. ("Tmunity") acquisition milestones met.
GILD 10-Kaccession 0000882095-25-000006
SentenceAcquired in-process research and development expenses were $1.2 billion in 2023, primarily related to the following transactions: • $313 million Arcellx collaboration; • $269 million Tmunity acquisition; • $218 million XinThera, Inc. acquisition; • $97 million Assembly Biosciences, Inc. collaboration; and • $60 million Compugen Ltd. licensing agreement.
GILD 10-Kaccession 0000882095-25-000006
SentenceEntered into an amended license agreement featuring the buy-out of global seladelpar royalties from Janssen Pharmaceutica NV for $320 million.
GILD 10-Kaccession 0000882095-25-000006
SentenceEffective December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV portfolio in Japan and to expand our rights to develop and commercialize elvitegravir to include Japan.
GILD 10-Kaccession 0000882095-25-000006
SentenceAcquired in-process research and development expenses were $4.7 billion in 2024, primarily related to the following transactions: • $3.8 billion CymaBay acquisition; • $320 million Janssen Pharmaceutica NV future royalty obligation extinguishment related to seladelpar; • $100 million Arcus Biosciences, Inc. collaboration continuation fee; • $68 million Arcellx, Inc. ("Arcellx") collaboration milestones met; and • $47 million Tmunity Therapeutics, Inc. ("Tmunity") acquisition milestones met.
GILD 10-Kaccession 0000882095-25-000006
SentenceAcquired in-process research and development expenses were $1.2 billion in 2023, primarily related to the following transactions: • $313 million Arcellx collaboration; • $269 million Tmunity acquisition; • $218 million XinThera, Inc. acquisition; • $97 million Assembly Biosciences, Inc. collaboration; and • $60 million Compugen Ltd. licensing agreement.
GILD 10-Kaccession 0000882095-25-000006
SentenceIn October 2023, we entered into an Option, License and Collaboration agreement (the Gilead Collaboration Agreement) with Gilead pursuant to which Gilead (1) exclusively licensed to us its HPI program and its NNPI program, while retaining opt-in rights to these programs, and (2) has an option to take an exclusive license, on a program-by-program basis, to all of our other current and future pipeline programs.
SentenceWe are conducting a Phase 1/2 clinical trial pursuant to a Clinical Study Collaboration and Supply Agreement (CSCSA) with Gilead to evaluate IDE397 in combination with Trodelvy (sacituzumab govitecan-hziy), Gilead's Trop-2 directed TOP1 ADC, in patients with MTAP-deletion urothelial cancer (UC), and non-small cell lung cancer (NSCLC).
SentenceIf any of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead's internal manufacturing infrastructure for their optioned products, as appropriate, to deliver commercial supply.
SentenceIn addition, we have an authorized generic version of Epclusa distributed by our separate subsidiary, Asegua Therapeutics LLC.
GILD 10-Kaccession 0000882095-25-000006
SentenceCencora, Inc. 18 % 19 % 18 %
GILD 10-Kaccession 0000882095-25-000006
SentenceSymtuza is commercialized by Janssen, and we receive a share in revenue for the components that we contribute.
GILD 10-Kaccession 0000882095-25-000006